Any current/future new fundraising through debt or equity?

For the current year, Hikal plans to complete ongoing capex with INR 200 crores, of which INR 100 crores is already completed. Some additional funding will be needed from the next quarter (H2 FY '24) to complete unfinished projects. There will be some debt funding in H2 FY '24, but this will be balanced by incoming equity. The company expects good profits in H2 FY '24, helping maintain debt-equity ratios around the current level (approximately 0.61). For the next year, capex will be slightly lower as efforts focus on utilizing existing assets, with no explicit mention of large new fundraising.

Any current/future capex/capital investment/strategic investment?

Current year capex planned is around INR 200 crores, with approximately INR 100 crores already completed. Next year's capex expected to be slightly lower, focusing on filling up existing assets rather than new expansions. Completion and commissioning of new facilities like the multipurpose Animal Health facility at Panoli are underway; full production ramp-up expected by March-April FY '25. Continuing investments in new plants, including Crop Protection assets, with commissioning starting soon. Asset capitalization occurs upon project completion, not at first commercial batch. Large

Future growth expectations in sales/revenue/volumes?

Volume growth for H1 FY24: Pharma volumes grew by 4%, Crop Protection volumes degrew by 26%, leading to overall 16% volume decline (Page 16). Crop Protection volume expected to improve starting Q4 FY24 with channel inventory normalization (Page 16). Sales growth targets: Management expects top line to grow substantially over the next 3-4 years with a target of INR 3,500-4,000 crores by FY26/FY27 (Page 10). New product launches and increased CDMO proportion in Pharma to support revenue growth (Pages 4, 11, 15). Capex completion and ramp-up expected by FY25 to drive incremental sales, wi

Future growth expectations in earnings/operating earnings/profits/EPS?

Pharma volumes grew 4% in H1 FY24; Crop Protection volumes degrew 26%, causing overall 16% decline. Signs of improvement in Crop Protection expected from Q4 FY24 as channel inventory normalizes. New product mix and CDMO business expected to improve margins significantly going forward. Capex commissioning for new plants anticipated by Q1/Q2 FY25, with ramp-up over 18-24 months. Revenue growth target of INR 3,500 to 4,000 crores by FY26-FY27 affirmed. Profitability and margins expected to improve sequentially in H2 FY24 due to cost optimization and better product mix. EBITDA margin expected to i

Current/ Expected Orderbook/ Pending Orders?

The earnings call transcript does not specify exact current orderbook or pending order values. Manoj Mehrotra highlighted increased customer inquiries and audits in the CDMO business, indicating a growing funnel of potential projects. Several new projects are under development due to increased new customer audits and exploration of new geographical markets. The Crop Protection business is at advanced stages of discussions with customers for new projects expected to yield positive medium- to long-term results. Validation batches for Animal Health products are planned over the next 4 to 6 quarte

IN US

Sale is live|00:00:00left today

Hikal LtdQ3 FY23Pharmaceuticals & Biotechnology

Hikal Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 103.9Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Volume growth for H1 FY24: Pharma volumes grew by 4%, Crop Protection volumes degrew by 26%, leading to overall 16% volume decline (Page 16).
→Crop Protection volume expected to improve starting Q4 FY24 with channel inventory normalization (Page 16).
→Sales growth targets: Management expects top line to grow substantially over the next 3-4 years with a target of INR 3,500-4,000 crores by FY26/FY27 (Page 10).
→New product launches and increased CDMO proportion in Pharma to support revenue growth (Pages 4, 11, 15).
→Capex completion and ramp-up expected by FY25 to drive incremental sales, with some ramp-up over 1-2 years post-commissioning (Pages 9-10).
→Ongoing customer interest and inquiries from new geographies in both Pharma and Crop Protection segments underpin growth optimism (Pages 7, 11, 15).

Margin guidance

Category 1

→Pharma volumes grew 4% in H1 FY24; Crop Protection volumes degrew 26%, causing overall 16% decline.
→Signs of improvement in Crop Protection expected from Q4 FY24 as channel inventory normalizes.
→New product mix and CDMO business expected to improve margins significantly going forward.
→Capex commissioning for new plants anticipated by Q1/Q2 FY25, with ramp-up over 18-24 months.
→Revenue growth target of INR 3,500 to 4,000 crores by FY26-FY27 affirmed.
→Profitability and margins expected to improve sequentially in H2 FY24 due to cost optimization and better product mix.
→EBITDA margin expected to increase 2-3% with CDMO ramp-up in H2 FY24.
→Debt levels stable; future expansion capex may require moderate funding but equity infusion and profits expected to maintain debt-equity ratio.
→ROE below cost of capital in Q2 FY24 seen as one-off; expected to recover with improved margins and volume growth.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→For the current year, Hikal plans to complete ongoing capex with INR 200 crores, of which INR 100 crores is already completed.
→Some additional funding will be needed from the next quarter (H2 FY '24) to complete unfinished projects.
→There will be some debt funding in H2 FY '24, but this will be balanced by incoming equity.
→The company expects good profits in H2 FY '24, helping maintain debt-equity ratios around the current level (approximately 0.61).
→For the next year, capex will be slightly lower as efforts focus on utilizing existing assets, with no explicit mention of large new fundraising.
→Overall, internal cash flows are expected to cover most expansion capex, but some measured debt and equity raising is anticipated to complete existing projects.

Order book

→The earnings call transcript does not specify exact current orderbook or pending order values.
→Manoj Mehrotra highlighted increased customer inquiries and audits in the CDMO business, indicating a growing funnel of potential projects.
→Several new projects are under development due to increased new customer audits and exploration of new geographical markets.
→The Crop Protection business is at advanced stages of discussions with customers for new projects expected to yield positive medium- to long-term results.
→Validation batches for Animal Health products are planned over the next 4 to 6 quarters, marking progress towards commercialization.
→The company expects CDMO demand to revive and normalization towards Q4 FY '24, implying an increase in orderbook going forward.
→Overall, the company is witnessing increased traction and new business inquiries across Pharma and Crop Protection segments, but no specific orderbacklog numbers were disclosed.

Capex plans

Yes

→Current year capex planned is around INR 200 crores, with approximately INR 100 crores already completed.
→Next year's capex expected to be slightly lower, focusing on filling up existing assets rather than new expansions.
→Completion and commissioning of new facilities like the multipurpose Animal Health facility at Panoli are underway; full production ramp-up expected by March-April FY '25.
→Continuing investments in new plants, including Crop Protection assets, with commissioning starting soon.
→Asset capitalization occurs upon project completion, not at first commercial batch.
→Large ongoing capex of approximately INR 500-550 crores over past years, with around INR 480-490 crores expected to be capitalized this year.
→Additional funding may be required in H2 for incomplete projects, but internal cash flows and equity infusion will keep debt-equity ratio stable (~0.61).
→Focus remains on technology, operational efficiency, and capacity ramp-up for medium to long-term growth.

How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hikal Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hikal Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio